STXS earnings analysis
What we found in STXS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Stereotaxis reported Q2 2026 revenue of $7.670 million, diluted EPS of $(0.05), and a 58% gross margin; revenue and EPS missed consensus, while gross margin improved year over year from 52.0% to 58%. Robotic catheter revenue exceeded $1 million, and management expects recurring revenue of approximately $7 million in Q3 and $8 million in Q4, plus $3 million of system revenue in each quarter. The outlook is constructive but execution and liquidity remain material risks because cash-flow profitability is not anticipated until the first half of 2027 and supplemental Robocath acquisition risks were added.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and EPS missed consensus
- Q2 2026 revenue was $7.670 million, while diluted EPS was $(0.05). Revenue was approximately 10.6% below the $8.580 million consensus estimate and EPS missed the $(0.04) estimate.
- Gross margin improved year over year
- Gross margin was 58% in Q2 2026, up from 52.0% in Q2 2025 and down from 60.3% in Q1 2026, indicating year-over-year improvement but sequential compression.
- Catheter adoption accelerated
- Robotic catheter revenue exceeded $1 million in Q2 2026, signaling accelerating adoption of the company’s recurring-product offering.
- Second-half revenue outlook provided
- Management expects recurring revenue of approximately $7 million in Q3 2026 and $8 million in Q4 2026, with system revenue of approximately $3 million in each quarter.
- Cash-flow breakeven targeted
- Management anticipates cash-flow profitability in the first half of 2027, providing a timing marker for the company’s path toward reduced cash consumption.
- Mixed operating trajectory
- The quarter’s diluted EPS of $(0.05) was weaker than the $(0.04) consensus estimate and unchanged from Q2 2025, while management’s outlook points to sequential recurring-revenue growth from $7 million in Q3 to $8 million in Q4.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Quarterly results missed estimates
- Q2 2026 revenue of $7.670 million missed the $8.580 million consensus estimate by approximately 10.6%, and diluted EPS of $(0.05) missed the $(0.04) estimate.
- Cash-flow breakeven remains distant
- The company remains dependent on execution to reach cash-flow profitability in the first half of 2027; the filing and related outlook provide no nearer-term cash-flow profitability date.
- Robocath integration risks added
- The 10-Q states that there were no material changes to the risk factors in the December 31, 2025 Form 10-K, except for supplemental risks related to the Robocath acquisition incorporated from the July 15, 2026 Form 8-K.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.05
- Gross margin
- 58.0%
- Segment
- Robotic catheter revenue exceeded $1 million in Q2 2026.
- Segment
- Recurring revenue outlook: approximately $7 million in Q3 2026 and $8 million in Q4 2026.
- Segment
- System revenue outlook: approximately $3 million in both Q3 2026 and Q4 2026.
What they said about what is next.
Management provided a second-half outlook of approximately $7 million recurring revenue and $3 million system revenue in Q3 2026, and approximately $8 million recurring revenue and $3 million system revenue in Q4 2026. Cash-flow profitability is anticipated in the first half of 2027; no comparable prior outlook was provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Stereotaxis reported a disappointing Q1 2026, with revenue of $6.3 million, falling short of the estimated $8.62 million. The gross margin improved to 60%, but operating losses widened, leading to an EPS of -$0.06,…
- 10-K · March 12, 2026
- Stereotaxis describes a strategy of expanding its Robotic Magnetic Navigation (RMN) franchise across electrophysiology and additional endovascular indications while commercializing new lab software (Synchrony / SynX)…
- 10-Q · May 13, 2025
- Stereotaxis posted quarterly revenue of $7.47M, up 8.6% from $6.88M a year ago, driven by a $5.51M disposables/services cohort (+29.0% YoY) while systems revenue declined. Gross margin dollars increased modestly to…
- 10-K · March 14, 2025
- Stereotaxis (STXS) describes a strategy of expanding its Robotic Magnetic Navigation (RMN) technology beyond electrophysiology into other endovascular indications, bolstered by the July 31, 2024 acquisition of Access…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing STXS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever